Gunel Tuba, Hosseini Mohammad Kazem, Gumusoglu Ece, Kisakesen Halil Ibrahim, Benian Ali, Aydinli Kilic
Istanbul University, Faculty of Science, Department of Molecular Biology and Genetics, Istanbul, Turkey.
Istanbul University, Faculty of Science, Department of Molecular Biology and Genetics, Istanbul, Turkey.
Placenta. 2017 Apr;52:77-85. doi: 10.1016/j.placenta.2017.02.019. Epub 2017 Feb 22.
Preeclampsia (PE) is one of the leading causes of maternal and fetal morbidity and mortality, occurring usually in the second half of pregnancy and affecting approximately 5-8% of pregnancies in the world. miRNAs play critical role in the regulation of placental development processes. We aimed to determine specific novel miRNAs for early diagnosis of preeclampsia which is one of the most dangerous pregnancy diseases. In this study 72 samples, maternal age 22 ≤ and ≤36, have been analyzed; maternal plasma and placental miRNAs were isolated from 18 severe preeclampsia (sPE) patients and 18 controls, respectively. Profiling of human miRNAs (1368 probe) was performed in samples with Agilent v16 microarrays for detection of the differences in miRNA expression between two groups. The results were validated by using TaqMan RT-qPCR method. The analysis indicated that 406 of these miRNAs in all placentas and 42 of these miRNAs in all maternal plasma were expressed. The relative expression analysis has shown that 12 miRNAs (p < 0.05 and >2-fold) in maternal plasma were differentially expressed in PE and control group. However, five miRNAs were validated by qRT-PCR. Once validated miRNAs have been searched in databases for their target genes and function, it has been shown that there are some preeclampsia related pathways as a target such as angiogenesis, cardiovascular, hypertension, placental abruption and preeclampsia disorders. Differentially expressed and validated plasma miRNAs might be used as notable biomarkers for non-invasive early diagnosis of preeclampsia and treatment of disease.
子痫前期（PE）是孕产妇和胎儿发病及死亡的主要原因之一，通常发生在妊娠后半期，影响全球约5-8%的妊娠。微小RNA（miRNA）在胎盘发育过程的调节中起关键作用。我们旨在确定用于子痫前期早期诊断的特定新型miRNA，子痫前期是最危险的妊娠疾病之一。在本研究中，分析了72例年龄在22≤且≤36岁的样本；分别从18例重度子痫前期（sPE）患者和18例对照中分离出母体血浆和胎盘miRNA。使用安捷伦v16微阵列对样本进行人类miRNA（1368个探针）分析，以检测两组之间miRNA表达的差异。结果通过TaqMan RT-qPCR方法进行验证。分析表明，所有胎盘中有406种这些miRNA表达，所有母体血浆中有42种这些miRNA表达。相对表达分析表明，母体血浆中有12种miRNA（p<0.05且>2倍）在PE组和对照组中差异表达。然而，通过qRT-PCR验证了5种miRNA。一旦在数据库中搜索已验证的miRNA的靶基因和功能，结果表明存在一些与子痫前期相关的途径作为靶点，如血管生成、心血管、高血压、胎盘早剥和子痫前期疾病。差异表达并经过验证的血浆miRNA可能作为子痫前期非侵入性早期诊断和疾病治疗的重要生物标志物。
